Glimepiride Canon pills 2mg, 30pcs

Composition

Active ingredient:

glimepiride 2 mg;

Auxiliary substances:

lactose monohydrate;

corn starch;

sodium carboxymethyl starch;

povidone;

polysorbate;

talc;

magnesium stearate;

iron dye (E 172)

Pharmacological action

Glimepiride Canon is a hypoglycemic drug for oral use-a new (third) generation sulfonylurea derivative. Glimepiride Canon works mainly by stimulating the secretion and release of insulin from the beta cells of the pancreas (pancreatic action).

As with other sulfonylurea derivatives, this effect is based on an increase in the response of pancreatic beta cells to physiological glucose stimulation, while the amount of insulin secreted is significantly lower than with traditional drugs-sulfonylurea derivatives. The lowest stimulating effect of glimepiride on insulin secretion also provides a lower risk of hypoglycemia. In addition to this, glimepiride has an extra-pancreatic effect – the ability to improve the sensitivity of peripheral tissues (muscle, fat) to the action of its own insulin, reduce the absorption of insulin by the liver; inhibits glucose production in the liver.

Glimepiride Canon selectively inhibits cyclooxygenase and reduces the conversion of arachidonic acid to thromboxane A2, which promotes platelet aggregation, thus exerting an antithrombotic effect.

Glimepiride Canon helps to normalize the lipid content, reduces the level of malic aldehyde in the blood, which leads to a significant decrease in lipid peroxidation, this contributes to the anti-atherogenic effect of the drug.

Glimepiride Canon increases the level of endogenous  alpha-tocopherol, catalase, glutathione peroxidase and superoxide dismutase activity, which helps to reduce the severity of oxidative stress in the patient’s body, which is constantly present in type 2 diabetes mellitus.

Indications

Type 2 diabetes mellitus.

Contraindications

Hypersensitivity, type 1 diabetes mellitus, diabetic ketoacidosis, diabetic precoma and coma, severe liver and kidney dysfunction, leukopenia, pregnancy, breast-feeding.

Side effects

Cardiovascular and blood disorders (hematopoiesis, hemostasis):  rarely — downgrade Blood pressure, thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, erythropenia, pancytopenia, hemolytic and aplastic anemia.

Nervous system and sensory disorders:  dizziness, headache, temporary visual impairment.

From the digestive tract:  nausea, vomiting, abdominal pain, heaviness in the epigastric region, diarrhea, intrahepatic cholestasis.

From the side of metabolism:  hypoglycemia.

Other services:  increased transaminase levels, hyponatremia, allergic skin reactions, late cutaneous porphyria, asthenia; rarely-shortness of breath, hepatitis, allergic vasculitis, photosensitization.

Interaction

The hypoglycemic effect of glimepiride may be enhanced when used concomitantly with insulin or other hypoglycemic drugs, ACE inhibitors, allopurinol, anabolic steroids and male sex hormones, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, phenyramidol, fibrates, fluoxetine, guanethidine, isophosphamides, MAO inhibitors, miconazole, PASC, pentoxifylline (when injected in high doses), phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolones, salicylates, sulfinpyrazone, sulfonamides, tetracyclines.

Weakening of the hypoglycemic effect of glimepiride is possible when used simultaneously with acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine (epinephrine) and other sympathomimetics, glucagon, laxatives (after prolonged use), nicotinic acid (in high doses), estrogens and progestogens, phenothiazine, phenytoin, rifampicin, thyroid hormones.

When used concomitantly, histamine H2-receptor blockers, clonidine and reserpine can both potentiate and reduce the hypoglycemic effect of glimepiride.

When using glimepiride, the effect of coumarin derivatives may increase or decrease.

Ethanol may increase or decrease the hypoglycemic effect of glimepiride.

How to take, course of use and dosage

The initial and maintenance dose is determined individually based on the results of regular monitoring of blood and urine glucose levels.

The initial dose is 1 mg once a day. If necessary, the daily dose can be gradually increased (by 1 mg in 1-2 weeks) to 4-6 mg.

The maximum dose is 8 mg / day.

Overdose

Symptoms:  hypoglycemia (nausea, vomiting and epigastric pain, restlessness, tremor, visual disturbances, coordination disorders, drowsiness, coma and convulsions).

Treatment:  if the patient is conscious – induction of vomiting, heavy drinking, activated charcoal and laxatives. In case of severe overdose-intravenous bolus use of dextrose solution (50 ml of 40% solution), followed by infusion of 10% solution. It is necessary to constantly monitor the patient, maintain vital functions and monitor the concentration of glucose in the blood (possible recurrence of episodes of hypoglycemia). Further treatment is symptomatic.

Composition

Tablet Form of production

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C, in a tightly sealed container.

Shelf life

5 years

Active ingredient

Glimepiride

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Type 2 Diabetes